Proteomic Biomarker Identification in Cerebrospinal Fluid for Leptomeningeal Metastases with Neurological Complications

Galicia, Norma; Díez, Paula; Dégano, Rosa Ma; Guest, Paul C.; Ibarrola, Nieves; Fuentes, Manuel

doi:10.1007/978-3-319-52479-5_5

Cited by 6 publications

(6 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the therapeutic advances in ALL, CNS relapse occurs in 3-8% of the children with ALL and is associated with increased morbidity and mortality [107]. In normal physiological conditions, 80% of the protein in the CSF is hematogenic in origin [108]. Thus, protein content changes in CSF provide an attractive approach to study hematological malignancies [109].…”

Section: Discussion-application Of Proteomics In Childhood Allmentioning

confidence: 99%

Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities

Kourti,

Aivaliotis,

Hatzipantelis

2023

Diagnostics

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is the most common cancer in children and one of the success stories in cancer therapeutics. Risk-directed therapy based on clinical, biologic and genetic features has played a significant role in this accomplishment. Despite the observed improvement in survival rates, leukemia remains one of the leading causes of cancer-related deaths. Implementation of next-generation genomic and transcriptomic sequencing tools has illustrated the genomic landscape of ALL. However, the underlying dynamic changes at protein level still remain a challenge. Proteomics is a cutting-edge technology aimed at deciphering the mechanisms, pathways, and the degree to which the proteome impacts leukemia subtypes. Advances in mass spectrometry enable high-throughput collection of global proteomic profiles, representing an opportunity to unveil new biological markers and druggable targets. The purpose of this narrative review article is to provide a comprehensive overview of studies that have utilized applications of proteomics in an attempt to gain insight into the pathogenesis and identification of biomarkers in childhood ALL.

show abstract

Section: Discussion-application Of Proteomics In Childhood Allmentioning

confidence: 99%

Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities

Kourti,

Aivaliotis,

Hatzipantelis

2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…LM is a devastating complication of malignancy that is characterized by the spread of cancer to the CNS and the formation of secondary tumors within the leptomeninges. Early detection of the disease and the early initiation of treatment remain essential to slow neurological deterioration [ 59 ]. As previously reported, LM diagnosis is mainly based on cytology in CSF or conventional flow cytometry immunophenotyping (together with the evaluation of neurological symptoms and imaging techniques).…”

Section: Discussionmentioning

confidence: 99%

“…Here, the identification of biomarkers to stratify patients according to their risk of developing LM is explored, and this would be of great benefit for both the diagnosis and prognosis of these individuals. In the last decade, proteomic-based approaches were increasingly used to identify biomarkers for a diverse range of diseases [ 35 , 59 ] Proteomics is the large-scale study of the proteome, and involves technologies for identification and quantification of a large proportion of the protein content, enabling the study of the complex and dynamic nature of the proteins [ 7 , 59 ].…”

Section: Discussionmentioning

confidence: 99%

Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid

Juanes-Velasco

Galicia

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

In the present work, leptomeningeal disease, a very destructive form of systemic cancer, was characterized from several proteomics points of view. This pathology involves the invasion of the leptomeninges by malignant tumor cells. The tumor spreads to the central nervous system through the cerebrospinal fluid (CSF) and has a very grim prognosis; the average life expectancy of patients who suffer it does not exceed 3 months. The early diagnosis of leptomeningeal disease is a challenge because, in most of the cases, it is an asymptomatic pathology. When the symptoms are clear, the disease is already in the very advanced stages and life expectancy is low. Consequently, there is a pressing need to determine useful CSF proteins to help in the diagnosis and/or prognosis of this disease. For this purpose, a systematic and exhaustive proteomics characterization of CSF by multipronged proteomics approaches was performed to determine different protein profiles as potential biomarkers. Proteins such as PTPRC, SERPINC1, sCD44, sCD14, ANPEP, SPP1, FCGR1A, C9, sCD19, and sCD34, among others, and their functional analysis, reveals that most of them are linked to the pathology and are not detected on normal CSF. Finally, a panel of biomarkers was verified by a prediction model for leptomeningeal disease, showing new insights into the research for potential biomarkers that are easy to translate into the clinic for the diagnosis of this devastating disease.

show abstract

“…HEMO is expressed in various tissues such as the nervous system, skeletal muscle, retina, kidney, but mainly in the liver [78]. HEMO was found at significantly different levels in the CSF of patients with leptomeningeal metastases of breast cancer with neurological complications [79] and with other neuropathologically confirmed diseases [80].…”

Section: The Promising Serum and Urinary Proteomic Biomarkers Of Medication-overuse Headachementioning

confidence: 99%

Candidate Genes and Proteomic Biomarkers of Serum and Urine in Medication-Overuse Headache

Shnayder

Sharavii

Петрова

et al. 2021

IJMS

View full text Add to dashboard Cite

Chronic headache is a topical problem of neurology, psychiatry and general practice. The medication-overuse headache (MOH) is one of the leading pathologies in the structure of chronic headache. However, early diagnosis of the MOH is challenging. We analyzed potential proteomic biomarkers of serum and urine in patients with MOH. Methods: We searched PubMed, Springer, Scopus, Web of Science, ClinicalKey, and Google Scholar databases for English publications over the past 10 years using keywords and their combinations. Results: We found and analyzed seven studies that met the search criteria for the purpose of the review, including 24 serum proteomic biomarkers and 25 urine proteomic biomarkers of MOH. Moreover, the candidate genes and locus of the studied serum (vitamin D-binding protein, lipocalin-type prostaglandin D2 synthase, apolipoprotein E, etc.) and urine proteomic biomarkers (uromodulin, alpha-1-microglobulin, zinc-alpha-2-glycoprotein, etc.) of MOH are presented in this review. Conclusions: The serum and urine proteomic biomarkers of MOH can potentially help with the identification of patients with MOH development. Due to the relevance of the problem, the authors believe that further investigation of the MOH proteomic biomarkers in different ethnic and racial groups of patients with primary headache is necessary. In addition, it is important to investigate whether medications of different drug classes influence the levels of serum and urine proteomic biomarkers.

show abstract

Proteomic Biomarker Identification in Cerebrospinal Fluid for Leptomeningeal Metastases with Neurological Complications

Cited by 6 publications

References 73 publications

Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities

Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities

Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid

Candidate Genes and Proteomic Biomarkers of Serum and Urine in Medication-Overuse Headache

Contact Info

Product

Resources

About